Gulani Anjana, Nagpal Jitender, Osmond Clive, Sachdev H P S
Department of Pediatrics and Clinical Epidemiology, Sitaram Bhartia Institute of Science and Research, B-16, Qutab Institutional Area, New Delhi 110016, India.
BMJ. 2007 May 26;334(7603):1095. doi: 10.1136/bmj.39150.510475.AE. Epub 2007 Apr 13.
To evaluate the effect of routine administration of intestinal anthelmintic drugs on haemoglobin.
Systematic review of randomised controlled trials.
Electronic databases and hand search of reviews, bibliographies of books, and abstracts and proceedings of international conferences.
Included studies were randomised or quasi-randomised controlled trials using an intestinal anthelmintic agent in the intervention group, in which haemoglobin was evaluated as an outcome measure. Trials in which treatment for schistosoma (praziquantel) was given exclusively to the intervention group were excluded.
The search identified 14 eligible randomised controlled trials. Data were available for 7829 subjects, of whom 4107 received an anthelmintic drug and 3722 received placebo. The pooled weighted mean difference (random effect model) of the change in haemoglobin was 1.71 (95% confidence interval 0.70 to 2.73) g/l (P<0.001; test for heterogeneity: Cochran Q=51.17, P<0.001; I(2)=61% (37% to 76%)). With the World Health Organization's recommended haemoglobin cut-offs of 120 g/l in adults and 110 g/l in children, the average estimated reduction in prevalence of anaemia ranged from 1.1% to 12.4% in adults and from 4.4% to 21.0% in children. The estimated reductions in the prevalence of anaemia increased with lower haemoglobin cut-offs used to define anaemia.
Routine administration of intestinal anthelmintic agents results in a marginal increase in haemoglobin (1.71 g/l), which could translate on a public health scale into a small (5% to 10%) reduction in the prevalence of anaemia in populations with a relatively high prevalence of intestinal helminthiasis.
评估常规使用肠道驱虫药物对血红蛋白的影响。
随机对照试验的系统评价。
电子数据库,并手工检索综述、书籍参考文献以及国际会议的摘要和论文集。
纳入的研究为干预组使用肠道驱虫药物的随机或半随机对照试验,其中血红蛋白作为结局指标进行评估。仅干预组接受血吸虫治疗(吡喹酮)的试验被排除。
检索到14项符合条件的随机对照试验。有7829名受试者的数据,其中4107人接受了驱虫药物,3722人接受了安慰剂。血红蛋白变化的合并加权平均差(随机效应模型)为1.71(95%置信区间0.70至2.73)g/l(P<0.001;异质性检验:Cochran Q=51.17,P<0.001;I²=61%(37%至76%))。按照世界卫生组织推荐的血红蛋白临界值,成人120 g/l,儿童110 g/l,成人贫血患病率估计平均降低幅度为1.1%至12.4%,儿童为4.4%至21.0%。用于定义贫血的血红蛋白临界值越低,贫血患病率估计降低幅度越大。
常规使用肠道驱虫药物可使血红蛋白略有增加(1.71 g/l),在公共卫生层面上,这可能会使肠道蠕虫病患病率相对较高的人群贫血患病率小幅降低(5%至10%)。